## 4th SURVEILLANCE CREDIT RATING REPORT KAZI PHARMECY

Ref. no.: CRAR-6058/2023



**Report Contents:** 

| Particulars                          | Page |
|--------------------------------------|------|
| Rating Rationale                     | 1    |
| Owners Profile                       | 2    |
| Business Management                  | 2    |
| Business Analysis                    | 2    |
| Financial Position<br>Analysis       | 4    |
| Banking Relationship and<br>Security | 4    |
| Risk Factor Analysis                 | 4    |
| Rating Observation                   | 4    |

# Rating NotchOutlookDate of DeclarationDate of ExpirationWCRSME3Stable17 October 202329 September 2024

Financial Based on- Management prepared financial statements up to 30 June 2023.

**Methodology:** SME Rating Methodology published on the WCRCL website at www.wasocreditrating.com

#### **Key Snapshot:**

BDT. in million

|                          | BDT. IN MIIIION |       |
|--------------------------|-----------------|-------|
| Particulars              | FY23            | FY22  |
| Revenue                  | 45.00           | 45.00 |
| EBIT                     | 1.10            | 1.00  |
| Net Profit               | 0.70            | 0.60  |
| <b>Total Assets</b>      | 25.55           | 21.10 |
| Total Equity             | 16.05           | 15.35 |
| Debt                     | 9.50            | 5.75  |
| Net Profit<br>Margin (%) | 1.6%            | 1.3%  |
| CCC (Days)               | 195             | 169   |
| ICR (X)                  | 2.79            | 2.54  |
|                          |                 |       |

#### **RATING RATIONALE**


WCRCL has reaffirmed **WCRSME3** (pronounced as WASO Credit Rating Small & Medium Enterprise Three) rating under the SME Rating to **Kazi Pharmecy** (hereinafter referred to as 'KP' or 'The Enterprise') based on its financial and other relevant qualitative and quantitative information up—to the date of the rating declaration.

The above ratings have been assigned based on the fundamentals of the enterprise which include long business experiences of the proprietor, moderate leverage position in the capital structure, healthy interest coverage position, and comfortable security arrangement. However, the above factors are constrained to some extent by manual accounting system, rented business premises, and lack of disclosure in the financial statements, and no insurance coverage for the inventory in stock

The SME rating implies that Kazi Pharmecy is adjudged to above average credit quality.

WCRCL also viewed Kazi Pharmecy with "Stable" outlook and believes that the enterprise will be able to maintain its good fundamentals in the foreseeable future. This rating may be revised in case of any extraordinary changes in line with the sponsor's equity investment, debt obligations, management, business operations and/or changes in any macro and micro factors in the economy.

### Capital Structure (BDT. in million)



#### Analysts:

Maharan Nasrin maharan@wasocreditrating.com

Md. Al Amin Jewel jewel@wasocreditrating.com